Scribd Logo
Upload

Welcome to Scribd!

  • 2 views

    Immune-Modulators and Thyroid Function in Oncological Patients With Hashimoto S Thyroiditis

    Uploaded by

    Scivision Publishers
    Hashimoto's thyroiditis (HT) is a form of chronic lymphocytic thyoriditis, of autoimmune origin and multiple physiopathogenic pathways, which may or may not be associated with other autoantibody diseases.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Immune-Modulators and Thyroid Function in Oncological Patients With Hashimoto S Thyroiditis

    Uploaded by

    Scivision Publishers
    2 views3 pages
    Hashimoto's thyroiditis (HT) is a form of chronic lymphocytic thyoriditis, of autoimmune origin and multiple physiopathogenic pathways, which may or may not be associated with other autoantibody diseases.

    Original Title

    Immune-Modulators and Thyroid Function in Oncological Patients with Hashimoto´S Thyroiditis

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Hashimoto's thyroiditis (HT) is a form of chronic lymphocytic thyoriditis, of autoimmune origin and multiple physiopathogenic pathways, which may or may not be associated with other autoantibody diseases.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    2 views3 pages

    Immune-Modulators and Thyroid Function in Oncological Patients With Hashimoto S Thyroiditis

    Uploaded by

    Scivision Publishers
    Hashimoto's thyroiditis (HT) is a form of chronic lymphocytic thyoriditis, of autoimmune origin and multiple physiopathogenic pathways, which may or may not be associated with other autoantibody diseases.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 3

    Research Article ISSN 2639-8478

    Research Article Cancer Science & Research

    Immune-Modulators and Thyroid Function in Oncological Patients with


    Hashimoto´S Thyroiditis
    Matozza Francesco1, Artero Guillermo H2, Artero Guillermo2, Levy Daniel4 and Carvallo Héctor5
    Service du Neuroradiologie, Hopital Henri-Mondor, Creteil,
    1

    France.
    *
    Correspondence:
    2
    Farmacéutico, Biopharmacie, France. Hector Carvallo, Endocrinologist, Member of S.A.E.M., Prof.
    Internal Medicine, Argentina.
    3
    Former Chief, Dept. Oncology, Htal. Rivadavia, Argentina.
    Received: 08 May 2021; Accepted: 10 June 2021
    Endocrinologist, Member of S.A.E.M., Prof. Internal Medicine,
    4

    Argentina.

    Citation: Francesco Matozza, Guillermo Artero H, Guillermo Artero, et al. Immune-Modulators and Thyroid Function in Oncological
    Patients with Hashimoto´S Thyroiditis. Cancer Sci Res. 2021; 4(2): 1-3.

    ABSTRACT
    Hashimoto's thyroiditis (HT) is a form of chronic lymphocytic thyoriditis, of autoimmune origin and multiple
    physiopathogenic pathways, which may or may not be associated with other autoantibody diseases, both
    endocrinological (P.A.S.) and non-endocrinological (M.A.S.). Likewise, HT can coincide -in the same patient- with
    very varied oncological pathologies, with which it can interact in a usually negative way. In this article, the benefit
    achieved in cancer patients who also had HT is evaluated through the use of immune-modulators.

    Keywords
    Hashimoto, Oncology, Immune-modulators.

    Introduction
    Hashimoto's thyroiditis (HT) is the most common cause of
    hypothyroidism worldwide (0.3-1.5 cases per 1,000 individuals
    per year) [1]. It is 7 times more frequent in the female sex. It is
    considered a disease of autoimmune origin, although a large
    number of dissimilar factors affect its physiopathogenesis [2,3].
    Likewise, an increased incidence of cancer has been observed and
    confirmed in patients with autoimmune diseases [4].

    Laboratory Findings at HT (Figure 1)


    1- Subclinical hypothyroidism (SCH)
    Normal T3 and T4 Increased TSH Increased ATG (anti
    Figure 1: HT Laboratory Findings.
    thyroglobulin)

    2- Clinical hypothyroidism (CH) Objectives


    Decreased T3 and T4 Increased TSH We proceeded to demonstrate the beneficial effect of immune-
    Increased anti-thyroid peroxidase (anti-TPO) modulators in patients with Hashimoto's Thyroiditis, who had
    different types of oncological pathologies.
    Increased antithyroglobulin (anti-Tg)

    Cancer Sci Res, 2021 Volume 4 | Issue 2 | 1 of 3


    Patients and Methods
    161 patients with Hashimoto's thyroiditis and different types of
    tumors were retrospectively evaluated in a multicenter study
    (Figure 2). Their age ranged from 40 to 70 years; 90% female.
    98 patients received cancer treatment plus immune-modulators
    and levothyroxine for 8 months.63 patients received only cancer
    treatment and levothyroxine as a control group, during the same
    period (Figure 3).

    Figures 4 & 5: A. membranaceus flowers and roots

    Simultaneously, it decreases immune hyperactivity in patients with


    systemic lupus erythematosus and myasthenia gravis. Selenium
    decreases antiperoxidase levels in patients with Hashimoto's
    thyroiditis [7].

    Method
    Figure 2: Types of tumors in the subjects that were controlled. T3, T4, TSH, TPO and TG antibodies were measured before, during,
    and up to 8 months after treatment with immune-modulators. The
    immune-modulators were administered orally, sublingually, at a
    dose of 4 ml per day.

    Results
    87 patients (78.5%) treated with Immunomodulators showed an
    increase in T3, T4 and a decrease in TSH, TPO and TG antibodies,
    two months after starting treatment. 8 (8.16%) patients showed
    no changes in thyroid function. 3 patients (3.06%) abandoned
    the treatment. Objectively, an increase in white blood cells, red
    blood cells, improvement of dry skin, asthenia, depression and
    intolerance to cold were observed. Subjectively, we observed
    a better quality of life in these patients treated with Immune-
    modulators (Figure 6).

    Figure 3: Distribution of patients with and without immune-modulators.

    Immune-Modulator
    The immune-modulator, which was used, is composed of Zinc,
    Selenium, Magnesium and Astragalus extract (Astragalus
    membranaceus) [5,6]. The constituents of this last compound are:
    glycosides, polysaccharides, isoflavone-type flavonoids, sucrose,
    phytosterols, such as beta-phytosterol. Astragalus has immune
    stimulating properties; it increases immune response, increases the
    activity of T lymphocytes and the absolute number of lymphocytes,
    stimulates the natural production of interferon and enhances its
    activity (Figure 4 and 5). Figure 6: Results.

    Cancer Sci Res, 2021 Volume 4 | Issue 2 | 2 of 3


    The control group did not show changes in thyroid function or On the other hand, in patients with uterine fibroids, ovarian
    variations in antibody levels (Figure 7). cysts, and / or mammary dysplasia, thyroid function (T3, T4,
    TSH, APTO, and ATG) should be studied routinely to rule out
    Hashimoto's disease.

    Immune-modulators are the best allies of cancer patients during


    and after chemo or radiotherapy treatment.

    They stimulate the immune system and improve the quality of life
    of these patients. In patients with coexisting Hashimoto's thyroiditis,
    immune-modulators show a marked clinical and laboratory improvement,
    with a marked reduction in supplementary hormone therapy.

    References
    1. Piraino, Patricia N, Sepúlveda, et al. Hashimoto chronic
    thyroiditis. Retrospective analysis of 228 patients. Revista
    Medica de Chile. 2018; 138: 827-831.
    2. Kahaly GJ. Polyglandular autoimmune síndromes. European
    Figure 7: Subjects´lab findings during study. Journal of Endocrinology. 2009.
    3. Ben-Skowronek, Michalczyk A, Piekarsk R. Type III
    Conclusions Polyglandular Autoimmune Syndromes in children with type
    Immune-modulators are well tolerated and have no side effects. 1 diabetes mellitus I. 2013.
    4. Angela Lopomo, Sonia Berrih-Aknin. Autoimmune
    They improve thyroid function in patients with Hashimoto's Thyroiditis and Myasthenia Gravis. Front Endocrinol
    thyroiditis. Lausanne. 2017; 8: 169.
    5. Mazokopakis EE, Papadakis JA, Papadomanolaki MG, et
    In cancer patients, immune-modulators also improve red blood
    al. Effects of 12 months treatment with L-selenomethionine
    cells, white blood cells, regulate platelets and improve the disease-
    on serum anti-TPO Levels in Patients with Hashimoto's
    free period.
    thyroiditis. Thyroid. 2007; 17: 609-612.
    As secondary findings, we may say that women with Hashimoto's 6. Mazokopakis EE, Chatzipavlidou V. Hashimoto's thyroiditis
    thyroiditis should have gynecological and imaging examinations and the role of selenium. Current concepts. Hell J Nucl Med.
    (mammography, breast ultrasound, transvaginal ultrasound, and 2007; 10: 6-8.
    PAP) more frequently, since they are more likely to develop 7. Kaprara A, Krassas GE. Selenium and thyroidal function the
    benign or malignant gynecological lesions. role of immunoassays Hell J Nucl Med. 2006; 9: 195-203.

    © 2021 Francesco Matozza, et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License

    Cancer Sci Res, 2021 Volume 4 | Issue 2 | 3 of 3

    You might also like